
BioHarvest Sciences fell 81.4% from $6.61 to $1.23, behind the S&P 500's +10.6%. Its worst day was Aug 10 (−18.0%), and its low came Nov 17 at $1.22.
Nov 18, 2025 – Nov 18, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
BioHarvest Sciences closed at its highest level of the year, 3.3% above where the year started.
+0.7% · S&P 500 +0.9%
EPS of $-0.10 beat the $-0.10 estimate on $9.1M revenue (est. $9.3M); FY revenue guidance of $42.0M–$48.0M against the $48.4M consensus.
Story events cover the past 12 months · Times ET
−0.7% · S&P 500 +0.8%
EPS of $-0.11 beat the $-0.12 estimate on $8.5M revenue (est. $8.8M); FY revenue guidance of $42.0M–$48.0M against the $44.7M consensus.
+3.9% · S&P 500 +0.8%
BioHarvest Sciences shares fell 15.9%, while the S&P 500 rose 0.8%.
−15.9% · S&P 500 +0.8%
EPS of $-0.17 missed the $-0.12 estimate on $8.8M revenue (est. $9.5M); FY revenue guidance of $37.0M–$40.0M against the $42.9M consensus.
−1.2% · S&P 500 −0.3%
Botanical Synthesis™-developed asset has now completed development, commercial-scale manufacturing and the applicable self-affirmed GRAS process and is ready for production at BioHarvest’s GMP facilityMilestone
+11.7% · S&P 500 0.0%
EPS of $-0.15 missed the $-0.14 estimate on $7.9M revenue (est. $9.4M); FY revenue guidance of $32.0M–$33.5M against the $37.5M consensus.
−4.5% · S&P 500 −0.4%
Where it ended: a close of $1.23 on Nov 18, 2026.
Nothing in the past 12 months.
All BHST dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for BHST and SPY from Benzinga historical bars. Not investment advice.